|
WO2021033144A1
|
|
Oral suspension of capecitabine
|
|
WO2021019493A1
|
|
Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate
|
|
WO2021009700A1
|
|
Pharmaceutical composition of temozolomide.
|
|
WO2021009686A1
|
|
Pharmaceutical composition of imatinib
|
|
WO2021005544A1
|
|
Stable oral composition of cyclophosphamide
|
|
WO2021005501A1
|
|
Naltrexone formulation
|
|
WO2020254952A1
|
|
A stable formulation of cetrorelix
|
|
WO2020222151A1
|
|
A stable, ready to use aqueous pharmaceutical composition of pemetrexed
|
|
WO2020183332A1
|
|
Purification of adalimumab using tandem chromatography
|
|
WO2020183295A1
|
|
Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
|
|
WO2020144607A1
|
|
A process for preparation of a stable pharmaceutical composition of bortezomib
|
|
EP3799864A1
|
|
Essentially sodium-free effervescent solid pharmaceutical compositions
|
|
WO2019197961A1
|
|
Pharmaceutical composition of nintedanib esylate
|
|
US2021100821A1
|
|
Stable lyophilized composition of cyclophosphamide
|
|
WO2019097413A1
|
|
Stable non-aqueous pharmaceutical compositions
|
|
WO2019077432A1
|
|
Improved purification method of recombinant pth (1-34)
|
|
WO2018142356A1
|
|
Pharmaceutical composition of everolimus
|
|
BR112019016028A2
|
|
PHARMACEUTICAL COMPOSITION OF CAPECITABINE
|
|
WO2018051292A1
|
|
Extended release pharmaceutical composition of clozapine
|
|
EP3431078A1
|
|
Non-pulsatile prolonged-release betahistine oral solid compositions
|
